At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 3,235 enrolled
Drug / intervention
Biolimus-eluting stent +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial
In Brief
A Phase 4 clinical trial evaluating Biolimus-eluting stent and Everolimus-eluting stent for Coronary Artery Disease. Completed, enrolled 3,235 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate whether the newly-approved biolimus-eluting stent is not inferior to the everolimus-eluting stent in terms of the rate of target-lesion revascularization at 1-year and death or myocardial infarction at 3-year after stent implantation in the real world clinical practice.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartMay 2011
Primary CompletionOct 2015
TodayJul 2026
First PostedFeb 25, 2011
Enrollment StartMay 1, 2011
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 15.4 years ago
Interventions
Biolimus-eluting stentdevice
Biolimus-eluting stent
Everolimus-eluting stentdevice
Everolimus-eluting stent